

In The Claims:

1. (Currently Amended) A bivalent or multivalent antibody characterized by the following features:
 - (a) it is capable of suppressing an immune reaction;
 - (b) it is devoid of constant antibody regions; and
 - (c) it ~~binds an epitope on the CD3 complex of the T-cell receptor~~ specifically binds to human TCR/CD3 complex.
2. (Original) The antibody of claim 1 that is a diabody.
3. (Original) The antibody of claim 1 that comprises two scFv antibodies linked by a peptide linker.
4. (Original) The antibody of claim 1 that is a single chain diabody.
5. (Previously Presented) The antibody according to claim 1, wherein its variable V_H and V_L domains are connected via the peptide linker SAKTTP (SEQ ID NO:1) or SAKTTPKLGG (SEQ ID NO:2).
6. (Previously Presented) The antibody according to claim 1, wherein its variable domains correspond to the variable domains of an antibody produced by the hybridoma of ATCC deposit number CRL 8001.
7. (Previously Presented) The antibody according to claim 6, wherein a cysteine at position H100A has been exchanged for another amino acid.
8. (Original) The antibody according to claim 7, wherein the cysteine has been exchanged for a serine.

9. (Withdrawn) A polynucleotide, which encodes an antibody according to claim 1.
10. (Withdrawn) An expression vector comprising the polynucleotide of claim 9.
11. (Withdrawn) The expression vector of claim 10, which is pSKK3-scFv_6-anti-CD3 (DSM 15137).
12. (Withdrawn) A host cell containing the expression vector of claim 10 or 11.
13. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 1 and a suitable pharmaceutical carrier.
14. (Withdrawn) A method for immunotherapy comprising the step of administering to a subject the pharmaceutical composition according to claim 13.
15. (Withdrawn) A method for immunotherapy comprising the step of administering to a subject a pharmaceutical composition comprising the antibody of claim 1.
16. (Withdrawn) The method according to claim 14, wherein said immunotherapy is a therapy against acute transplant rejections.
17. (Withdrawn) A method for gene therapy comprising the step of administering to a subject a pharmaceutical composition comprising the polynucleotide of claim 9 or the expression vector of claim 10.
18. (Previously Presented) The antibody according to claim 1, wherein the antibody is purified.
19. (Previously Presented) The pharmaceutical composition of claim 13, wherein the suitable pharmaceutical carrier is selected from the group consisting of emulsions, wetting agents and sterile solutions.

20. (New) The pharmaceutical composition of claim 13, wherein the composition is a sterile solution.